Therapy Areas: Inflammatory Diseases
Celgene Provides Update on Abraxane Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
14 March 2019 - - US-based biopharmaceutical company Celgene Corp. (NASDAQ: CELG) has produced two updates for Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) i...
The US Food and Drug Administration approves Regeneron and Sanofi's Dupixent
14 March 2019 - The US Food and Drug Administration (FDA) has approved United States-based Regeneron Pharmaceuticals' and France-based Sanofi's Dupixent (dupilumab) for adolescent patients 1...
Regeneron Pharmaceuticals Inc wins US FDA approval for Dupixent to treat moderate-to-severe atopic dermatitis
13 March 2019 - Biotechnology company Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi Tuesday jointly announced on Tuesday that the US Food and Drug Administration (FDA) has approved Dupixent f...
Escient Pharmaceuticals Names Hodder as Chief Business Officer
12 March 2019 - - William Hodder has joined US-based biotechnology company Escient Pharmaceuticals, Inc. as chief business officer, the company said.

Hodder brings more than 30 years of b...
Adare Pharmaceuticals Achieves Primary End-Point in Phase IIb Study (FLUTE) for APT-1011 in Patients with Eosinophilic Esophagitis
12 March 2019 - - US-based Adare Pharmaceuticals (Adare) has received positive results from its Phase IIb study (FLUTE) for one of its rare disease investigational products, APT-1011 (AdvaTab Fluticas...
Sanofi wins US FDA approval for Dupixent to treat adolescent patients with moderate-to-severe atopic dermatitis
12 March 2019 - Biotechnology company Sanofi (EURONEXT:SAN) (NASDAQ:SNY) reported on Monday the receipt of approval for Dupixent to help clear the skin and reduce itching in adolescent patients with m...